Skip to content

Hypervirulent Amoxicillin-Susceptible Klebsiella Pneumoniae CC66, France, 2016-2023

Genomic and Clinical Characterization of Amoxicillin-Susceptible Klebsiella Pneumoniae, Including Hypervirulent Clonal Complex 66, in a French University Hospital (2016-2023)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07598006
Enrollment
56
Registered
2026-05-20
Start date
2016-01-01
Completion date
2025-12-12
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections, Sepsis

Brief summary

"Klebsiella pneumoniae is considered intrinsically resistant to ampicillin because of the chromosomal blaSHV β-lactamase. However, amoxicillin-susceptible isolates have been sporadically reported. This retrospective observational study analyzes amoxicillin-susceptible K. pneumoniae isolates collected between 2016 and 2023 at a university hospital in France. Whole-genome sequencing, phylogenetic analysis, and virulence and resistance profiling were performed, and clinical data were reviewed. The study aims to characterize the genomic mechanisms underlying amoxicillin susceptibility and to assess associations with specific lineages, particularly hypervirulent clonal complex 66 (CC66), and clinical features."

Interventions

BIOLOGICALBacterial species identification by Whole Genome sequencing

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with confirmed Klebsiella pneumoniae infection. * Isolates collected between 2016 and 2023. * Isolates with confirmed susceptibility to amoxicillin.

Exclusion criteria

* Isolates not confirmed as Klebsiella pneumoniae. * Isolates without antimicrobial susceptibility confirmation.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of blaSHV gene status (presence, deletion, or disruptive mutations) by whole-genome sequencing and its association with amoxicillin susceptibility.At isolate collection and genomic analysis (2016-2023)Whole-genome sequencing was used to determine blaSHV gene status (presence, absence, or disruptive mutations)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026